Sangamo Therapeutics Inc <SGMO.OQ> expected to post a loss of 13 cents a share - Earnings Preview

• Sangamo Therapeutics Inc SGMO.OQ SGMO.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025

• The Richmond California California-based company is expected to report a 8,798.9% increase in revenue to $31.68 million from $356 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Sangamo Therapeutics Inc is for a loss of 13 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $2.00, about 73.1% above its last closing price of $0.54

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated August 1 at 11:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)